Limits...
Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X - Theranostics (2015)

Bottom Line: Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET.In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions.This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital), Wuxi, China.

ABSTRACT
This pilot prospective evaluation study is to verify the efficiency of (18)F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to (18)F-FDG PET. Thirty recruited patients underwent (18)F-FDG and (18)F-alfatide II PET/CT successively within days. The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow. Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET. Eleven patients were found to have a total of 126 bone metastasis lesions. (18)F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than (18)F-FDG PET (77%). Especially, (18)F-Alfatide II PET showed superiority to (18)F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%). In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions. The sensitivity of (18)F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of (18)F-FDG PET/CT. This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

No MeSH data available.


Related in: MedlinePlus

2D projection images of 18F-Alfatide II PET (A) and 18F-FDG PET (B) of a patient (no. 2) with metastatic adenocarcinoma of unknown primary site. 18F-Alfatide II PET demonstrated intense local accumulation of radioactivity in bone metastatic lesions located in thoracic vertebras, sacrum and right scapula, and right clavicle with good background contrast, whereas 18F-FDG PET only showed moderate uptake in some thoracic vertebras and sacral lesions. The transaxial CT (C), 18F-Alfatide II PET (D), and 18F-FDG PET (E) were presented to focus on the lesions at sacrum. There is also bone metastasis with abnormal 18F-Alfatide II uptake (G) but not visible by transaxial CT (F) or 18F-FDG PET (H).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4508500&req=5

Figure 1: 2D projection images of 18F-Alfatide II PET (A) and 18F-FDG PET (B) of a patient (no. 2) with metastatic adenocarcinoma of unknown primary site. 18F-Alfatide II PET demonstrated intense local accumulation of radioactivity in bone metastatic lesions located in thoracic vertebras, sacrum and right scapula, and right clavicle with good background contrast, whereas 18F-FDG PET only showed moderate uptake in some thoracic vertebras and sacral lesions. The transaxial CT (C), 18F-Alfatide II PET (D), and 18F-FDG PET (E) were presented to focus on the lesions at sacrum. There is also bone metastasis with abnormal 18F-Alfatide II uptake (G) but not visible by transaxial CT (F) or 18F-FDG PET (H).

Mentions: Normally, the highest activity of 18F-Alfatide II was found in the kidneys and bladder, demonstrating predominant renal clearance of the tracer. Liver, spleen, and intestines also showed moderate uptake, while normal bone and bone marrow had very low background level of radioactivity distribution. Therefore, 18F-Alfatide II PET has the potential to visualize bone metastatic lesions with high contrast to surrounding background (Figure 1).


Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X - Theranostics (2015)

2D projection images of 18F-Alfatide II PET (A) and 18F-FDG PET (B) of a patient (no. 2) with metastatic adenocarcinoma of unknown primary site. 18F-Alfatide II PET demonstrated intense local accumulation of radioactivity in bone metastatic lesions located in thoracic vertebras, sacrum and right scapula, and right clavicle with good background contrast, whereas 18F-FDG PET only showed moderate uptake in some thoracic vertebras and sacral lesions. The transaxial CT (C), 18F-Alfatide II PET (D), and 18F-FDG PET (E) were presented to focus on the lesions at sacrum. There is also bone metastasis with abnormal 18F-Alfatide II uptake (G) but not visible by transaxial CT (F) or 18F-FDG PET (H).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4508500&req=5

Figure 1: 2D projection images of 18F-Alfatide II PET (A) and 18F-FDG PET (B) of a patient (no. 2) with metastatic adenocarcinoma of unknown primary site. 18F-Alfatide II PET demonstrated intense local accumulation of radioactivity in bone metastatic lesions located in thoracic vertebras, sacrum and right scapula, and right clavicle with good background contrast, whereas 18F-FDG PET only showed moderate uptake in some thoracic vertebras and sacral lesions. The transaxial CT (C), 18F-Alfatide II PET (D), and 18F-FDG PET (E) were presented to focus on the lesions at sacrum. There is also bone metastasis with abnormal 18F-Alfatide II uptake (G) but not visible by transaxial CT (F) or 18F-FDG PET (H).
Mentions: Normally, the highest activity of 18F-Alfatide II was found in the kidneys and bladder, demonstrating predominant renal clearance of the tracer. Liver, spleen, and intestines also showed moderate uptake, while normal bone and bone marrow had very low background level of radioactivity distribution. Therefore, 18F-Alfatide II PET has the potential to visualize bone metastatic lesions with high contrast to surrounding background (Figure 1).

Bottom Line: Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET.In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions.This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital), Wuxi, China.

ABSTRACT
This pilot prospective evaluation study is to verify the efficiency of (18)F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to (18)F-FDG PET. Thirty recruited patients underwent (18)F-FDG and (18)F-alfatide II PET/CT successively within days. The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow. Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET. Eleven patients were found to have a total of 126 bone metastasis lesions. (18)F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than (18)F-FDG PET (77%). Especially, (18)F-Alfatide II PET showed superiority to (18)F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%). In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions. The sensitivity of (18)F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of (18)F-FDG PET/CT. This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

No MeSH data available.


Related in: MedlinePlus